title: mRNA vaccine delivery using lipid nanoparticles.
abstract: mRNA vaccines elicit a potent immune response including antibodies and cytotoxic T cells. mRNA vaccines are currently evaluated in clinical trials for cancer immunotherapy applications, but also have great potential as prophylactic vaccines. Efficient delivery of mRNA vaccines will be key for their success and translation to the clinic. Among potential nonviral vectors, lipid nanoparticles are particularly promising. Indeed, lipid nanoparticles can be synthesized with relative ease in a scalable manner, protect the mRNA against degradation, facilitate endosomal escape, can be targeted to the desired cell type by surface decoration with ligands, and as needed, can be codelivered with adjuvants.
authors.affiliation: Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.|David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
authors.forename: Andreas M
authors.initials: AM
authors.lastname: Reichmuth
authors.affiliation: Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.|David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
authors.forename: Matthias A
authors.initials: MA
authors.lastname: Oberli
authors.affiliation: David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
authors.forename: Ana
authors.initials: A
authors.lastname: Jaklenec
authors.affiliation: Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.|David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.|Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA.|Harvard-MIT Division of Health Sciences & Technology, Massachusetts Institute of Technology, Cambridge, MA, USA.|Department of Anesthesiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Langer
authors.affiliation: Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Blankschtein
mesh_terms: D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods*; D008055:Lipids / Q000008:administration & dosage*; D008251:Macaca; D051379:Mice; D053758:Nanoparticles; D012333:RNA, Messenger / Q000008:administration & dosage*; D011817:Rabbits; D014612:Vaccines / Q000008:administration & dosage*
chemical_list: D008055:Lipids; D012333:RNA, Messenger; D014612:Vaccines
keywords: adjuvant; cancer immunotherapy; cationic lipid; drug delivery; lipid nanoparticle; mRNA; oligonucleotide; therapeutic vaccine; vaccine